" class="no-js "lang="en-US"> Erika Hamilton - Medtech Alert
Saturday, September 13, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Erika Hamilton

Erika Hamilton

About Erika Hamilton

Erika P Hamilton, MD, cares for patients with breast and gynecologic cancer. As the director of the breast cancer and gynecologic cancer research program at Sarah Cannon Research Institute, she oversees the program and the clinical trial menu for these cancers across the Sarah Cannon network.

Related Story

Diseases

 Enhertu Approved in the US for Patients with HER2-positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-based Regimen | Pharmtech Focus

Enhertu Approved in the US for Patients with HER2-positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-based Regimen

May 6 2022

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of […]